Supplementary Materials

Supplementary Material for:

Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses

Nicholas J. Roberts, Linping Zhang, Filip Janku, Amanda Collins, Ren-Yuan Bai, Verena Staedtke, Anthony W. Rusk, David Tung, Maria Miller, Jeffrey Roix, Kristen V. Khanna, Ravi Murthy, Robert S. Benjamin, Thorunn Helgason, Ariel D. Szvalb, Justin E. Bird, Sinchita Roy-Chowdhuri, Halle H. Zhang, Yuan Qiao, Baktiar Karim, Jennifer McDaniel, Amanda Elpiner, Alexandra Sahora, Joshua Lachowicz, Brenda Phillips, Avenelle Turner, Mary K. Klein, Gerald Post, Luis A. Diaz Jr., Gregory J. Riggins, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Chetan Bettegowda, David L. Huso, Mary Varterasian, Saurabh Saha,* Shibin Zhou

*Corresponding author. E-mail: saurabh.saha@gmail.com

Published 13 August 2014, Sci. Transl. Med. 6, 249ra111 (2014)
DOI: 10.1126/scitranslmed.3008982

This PDF file includes:

  • Fig. S1. Response to intratumoral C. novyi-NT treatment in rat orthotopic brain tumor model.
  • Fig. S2. Survival analysis of dogs treated with intratumoral injection of C. novyi-NT.
  • Table S1. Summary data for samples sequenced.
  • Table S2. Somatic alterations in canine sarcomas.
  • Table S3. Copy number alterations in canine sarcomas.
  • Table S4. Type of somatic changes observed across canine soft tissue sarcomas.
  • Table S5. Type of somatic mutations across canine soft tissue sarcomas.
  • Table S6. Genes mutated in both human and canine cancers.
  • Table S7. Summary of study evaluations.
  • Table S8. Summary of adverse events observed throughout study.
  • Table S9. Performance status evaluations.
  • Table S10. Coded terms to describe tumor adverse events associated with C. novyi-NT activity.
  • Table S11. Signs not attributable in VeDDRA to underlying clinical entity or C. novyi-NT–related target lesion reaction.

[Download PDF]